cellsciences.com

SERPINE1 Recombinant Human Serpin E1/PAI-1 Stable Vitronectin Reduced-Binding Point Mutant

Catalog No.	CSI20514A CSI20514B	Quantity:	0.5 mg 1.0 mg
Alternate Names:	Plasminogen activator inhibitor type 1, PAI, PAI1, PAI-1, PLANH1, Serpin peptidase inhibitor, clade E, SERPINE1,		
Description:	 Plasminogen Activator Inhibitor 1 (PAI-1), also known as Serpin peptidase inhibitor, clade E (SERPINE1), is a member of the serine protease inhibitor (serpin) superfamily. It is the principal inhibitor of Tissue Plasminogen Activator (tPA) and Urokinase (uPA), the activators of Plasminogen and hence fibrinolysis. PAI-1 is mainly produced by the endothelium, but is also secreted by other tissue types, such as adipose tissue. Defects in the PAI-1 gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the protein are associated with thrombophilia. The Recombinant Human Serpin E1/PAI-1 Stable Vitronectin Reduced-Binding Point Mutant is produced by the mutagenesis of the Q123K residue on the Human Serpin E1/PAI-1 stable mutant background (K154T, Q319L, M354I and N150H) resulting in a PAI-1 with greatly extended half life and reduced binding to the vitronectin ligand. 		
Concentration:	2.5 mg/ml		
Gene ID:	5054		
Source:	E. coli		
Molecular Weight:	43 kDa		
Formulation:	Frozen Liquid in 0.05 M Sodium Phosphate + 0.1 M NaCl + 1 mM EDTA, pH 6.6		
Purity:	>95% by SDS-PAGE		
Endotoxin Level:	< 0.1 ng/µg of protein.		
Storage & Stability:	Store at -80°C. Stable for 3 years from delivery. For long term use, divide into working aliquots and freeze at -80°C. Avoid repeated freeze-thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

